Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7365)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 26, 2018 (publication date) through May 17, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhou J, Chooi JY, Ching YQ, Quah JY, Toh SHM, Ng Y, Tan TZ, Chng WJ. NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B. World J Stem Cells 2018; 10(4): 34-42 [PMID: 29707103 DOI: 10.4252/wjsc.v10.i4.34] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v10/i4/34.htm |
| Number | Citing Articles |
| 1 |
Barbara Di Francesco, Daniela Verzella, Daria Capece, Davide Vecchiotti, Mauro Di Vito Nolfi, Irene Flati, Jessica Cornice, Monica Di Padova, Adriano Angelucci, Edoardo Alesse, Francesca Zazzeroni. NF-κB: A Druggable Target in Acute Myeloid Leukemia. Cancers 2022; 14(14): 3557 doi: 10.3390/cancers14143557
|
| 2 |
Chune Ren, Xue Han, Chao Lu, Tingting Yang, Pengyun Qiao, Yonghong Sun, Zhenhai Yu. Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death & Differentiation 2022; 29(2): 381 doi: 10.1038/s41418-021-00862-4
|
| 3 |
Jianbiao Zhou, Wee-Joo Chng. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World Journal of Clinical Oncology 2018; 9(5): 90-97 doi: 10.5306/wjco.v9.i5.90
|
| 4 |
Ana Carolina B. da C. Rodrigues, Rafaela G.A. Costa, Suellen L.R. Silva, Ingrid R.S.B. Dias, Rosane B. Dias, Daniel P. Bezerra. Cell signaling pathways as molecular targets to eliminate AML stem cells. Critical Reviews in Oncology/Hematology 2021; 160: 103277 doi: 10.1016/j.critrevonc.2021.103277
|
| 5 |
Yunlu Jia, Wee-Joo Chng, Jianbiao Zhou. Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. Journal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-019-0757-y
|
| 6 |
Salihanur Darici, Hazem Alkhaldi, Gillian Horne, Heather G. Jørgensen, Sandra Marmiroli, Xu Huang. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. Journal of Clinical Medicine 2020; 9(9): 2934 doi: 10.3390/jcm9092934
|
| 7 |
Mahdi Pakjoo, Seyed Esmaeil Ahmadi, Mohammad Zahedi, Niloofar Jaafari, Reyhane Khademi, Ali Amini, Majid Safa. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Communication and Signaling 2024; 22(1) doi: 10.1186/s12964-023-01433-5
|